Veloxis Pharmaceuticals A/S (OMX: VELO) and Chiesi Farmaceutici S.p.A. today announced that the European Commission (EC) has granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU). Key points: The EMA marketing authorization is based on review of the favorable results of...
Leading Experts from the Bone Infection Unit at the Nuffield Orthopaedic Centre in Oxford Explore the Impact of New Surgical Strategies and the Threat of Antibiotic Resistance. 
Ness Ziona, Israel – August 4, 2014 – Atox Bio today announced that the European Commission has granted AB103 (Sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH) orphan medicinal product designation (EU/3/14/1294) for the treatment of necrotizing soft tissue infections. Atox Bio is represented in the EU by Dr. Ulrich Granzer as agent. In addition...
  SAN DIEGO, Aug. 1, 2014 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that it has entered into a credit facility with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) and its affiliate lenders. The credit facility provides for...
Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections 
License Brings Novel Gene Therapy Approach for in situ Targeting of Multi-Potent Stem Cells for the Heart
A bright European student was in the spotlight together with scientists and organizations when the Lundbeck Foundation awarded their prizes for best communication at ESOF2014 in Copenhagen.
The Lundbeck Foundation has appointed Lene Skole as new CEO.
Lund, Sweden, (PRNEWSWIRE) June 18, 2014 – BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to ortphopedic surgery, announced initiation of a CERAMENTT’G Bone Healing study by the CHUV (Centre Hospitalier Universitaire Vaudous), in Lausanne, Switzerland. The CERAMENTT’G Bone Healing study is a prospective, controlled, cohort...
1 2 3 4 5 6 8


Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge